Interventional Pharmacoeconomics

Daniel A. Goldstein, Garth W. Strohbehn, Anthony V. Serritella, David A. Hyman, Allen S. Lichter, Mark J. Ratain

Research output: Contribution to journalArticle

Abstract

The increasing cost of health care is a major challenge around the world, but particularly in the United States. One reason for increased costs is the rapidly rising cost of oncology drugs. Potential solutions to this problem involve broad changes to health policy. However, an alternative solution is the development of lower-cost off-label treatment regimens, based on pharmacologic rationale, with significant potential economic impact. The pharmacologic and clinical properties of many drugs allow for a variety of different strategies. We describe this approach of interventional pharmacoeconomics and provide multiple individual examples.

Original languageEnglish (US)
Pages (from-to)330-334
Number of pages5
JournalCancer journal (Sudbury, Mass.)
Volume26
Issue number4
DOIs
StatePublished - Jul 1 2020
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Interventional Pharmacoeconomics'. Together they form a unique fingerprint.

Cite this